How Can We Restore Freedom and Sound Money in the US and the UK? Some Ideas

Nvidia Smashes Estimates With Record Revenue And Blowout Guidance; Stock Jumps Heading into NVDA's earnings, we said that all else equal, the bare minimum for the stock - which has underperformed peers rather dramatically in recent months - to outperform, was to (solidly) beat expectations of another 2+2 quarter, i.e., beat the guide by $2BN and beat Street expectations for the April quarter guide by $2BN.  What they got was a blowout 2.2+5: Q4 revenues beating by $2.2BN and guidance beating the midpoint by about $5BN Here are the details from the just...

GLP-1 Feud Ends: NOVO, HIMS Join Forces (Again) To Sell Obesity Drugs The epic, months-long GLP-1 feud between Novo Nordisk and telehealth firm Hims & Hers Health appears to be coming to a surprising end, with both companies reportedly set to announce, as soon as Monday, a new partnership that would allow the Danish drugmaker to sell Wegovy through HIMS' platform. Bloomberg published the report late Friday, stating: Novo Nordisk A/S plans to sell its weight-loss drugs on Hims & Hers Health Inc.'s platform, according to a person familiar with the matter... ... Novo...

Ozempic Slims America... And It's Lightening Truckers' Loads! Via Freightwaves.com, The freight market is no stranger to disruptive forces - tariffs, recessions, weather, economic fluctuations, and capacity crunches have all reshaped freight demand over the years. But a new contender is emerging from an unexpected corner: the widespread adoption of GLP-1 medications (think Ozempic, Wegovy, Mounjaro, and similar GLP-1 receptor agonists). These drugs, originally developed for diabetes management and now massively popular for weight loss, suppress appetite and reduce overall caloric intake. Early estimates suggest that even at current penetration levels — roughly 12%...